Sandhill Capital Partners LLC Gain Therapeutics, Inc. Transaction History
Sandhill Capital Partners LLC
- $1.15 Billion
- Q1 2025
A detailed history of Sandhill Capital Partners LLC transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Sandhill Capital Partners LLC holds 15,400 shares of GANX stock, worth $31,108. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,400
Previous 15,400
-0.0%
Holding current value
$31,108
Previous $31,000
6.45%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.1MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.19 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.14 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$570,0660.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$515,0790.0% of portfolio
-
Marshall Wace, LLP London, X0196KShares$395,9720.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $24M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...